Skip to main content

Advertisement

SpringerLink
Log in

Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Oxaliplatin 100 mg/m2 iv on day 1, and capecitabine 1,000 mg/m2 orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma. A total of 318 cycles were administered, with a median of 8 (range, 4–12) cycles per patient. Response rate (RR) was 45% (95% confidence interval (CI), 29%–62%), with 7 complete responses and 10 partial responses; furthermore, 12 patients showed a stable disease, so that a disease control was achieved in 29 (76%) patients. RR was greater among patients with performance status 0 (52%), without weight loss (52%), younger than 65 years (50%), and previously unexposed to adjuvant chemotherapy (48%), while no correlation was found with the actually delivered oxaliplatin dose intensity. Overall, haematological side effects were negligible, with no case of grade 4 toxicity, and only one patient suffering from an episode of grade 3 neutropenic fever. Severe anaemia occurred in 4 (11%) patients, and grade 3 neuropathy affected 9 (24%) patients. Median progression-free survival was 7.9 (95% CI, 6.2–9.6) months, and median overall survival has not been reached yet. In conclusion, the OXXEL regimen resulted safe and active, and it deserves further evaluation in metastatic colorectal cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Borner MM, Dietrich D, Stupp R et al (2002) Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20:1759–1766

    Google Scholar 

  2. Cassidy J, Tabernero J, Twelves C, et al (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Onc 22:2084–2091

    Google Scholar 

  3. Comella P, Massidda B, Filippelli G, et al (2004) Oxaliplatin (OXA) plus levo-folinic acid (l-FA) and 5-fluorouacil (FU) i.v. bolus (OXAFAFU) is more active than irinotecan (IRI) plus levo-folinic acid (l-FA) and 5-fluorouacil (FU) i.v. bolus (IRIFAFU) in advanced colorectal carcinoma (ACC): Final results of the Southern Italy Cooperative Oncology Group (SICOG) trial 0103. Ann Oncol 15 (Supplement 3): iii72, abstract# 271PD

    Google Scholar 

  4. Cox DR (1970) The analysis of binary data. Methnem, London

    Google Scholar 

  5. De Gramont A, Cervantes A, André T et al (2004) OPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX4 in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 251s, abstract# 3525

    Google Scholar 

  6. Fisher GA, Kuo T, Cho CD et al (2004) A phase II study of Gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 248s, abstract# 3514

  7. Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30

    Google Scholar 

  8. Grothey A, Jordan K, Kellner O et al (2003) Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial. Eur J Cancer S90, abstract# 295

  9. Hoff PM, Ansari R. Batisti G et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282–2292

    Google Scholar 

  10. Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Google Scholar 

  11. Maindrault-Gœbel F, de Gramont A, Louvet C et al (2000) Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 11:1477–1483

    Article  PubMed  Google Scholar 

  12. Maindrault-Gœbel F, de Gramont A, Louvet C et al (2001) High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37:1000–1005

    Article  PubMed  Google Scholar 

  13. Miller AB, Hoogstraten B, Staquet M, Winkler V (1981) Reporting results of cancer treatment. Cancer 47:207–214

    CAS  PubMed  Google Scholar 

  14. Scheithauer WS, Kornek GV, Raderer M, et al (2003) Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 21:1307–1312

    Google Scholar 

  15. Simon R (1989) Optimal two stage design for phase II clinical trials. Contr Clin Trial 10:1–10

    Google Scholar 

  16. Tabernero JM, Van Cutsem E, Sastre J et al (2004) An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLOFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR): Preliminary results. Proc Am Soc Clin Oncol 248s, abstract# 3512

  17. Twelves C, on behalf of the Xeloda Colorectal Cancer Group (2002) Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Eur J Cancer 38:S15–S20

    Article  CAS  PubMed  Google Scholar 

  18. Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097–4106

    PubMed  Google Scholar 

  19. Zeuli M, Nardoni C, Pino MS et al (2003) Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 14:1378–1382

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology A, Department of Medicine, National Tumour Institute, Via M. Semmola, 80131, Naples, Italy

    P. Comella & R. Casaretti

  2. Chair of Medical Oncology, University Medical School, Via Jenner, 09100, Cagliari, Italy

    B. Massidda

  3. Chair of Medical Oncology, University Medical School, Piazza delle Cliniche 2, 90127, Palermo, Italy

    S. Palmeri

  4. Chair of Medical Oncology, University Medical School, Viale San Pietro 8, 07100, Sassari, Italy

    A. Farris

  5. Unit of Medical Oncology, City Hospital, Via Tescione 81, 81100, Caserta, Italy

    L. De Lucia

  6. Unit of Medical Oncology, San Massimo Hospital, Via Battaglione degli Alpini, 65017, Penne, Italy

    D. Natale

  7. Unit of Medical Oncology, San Gennaro Hospital, Via San Gennaro, 80100, Naples, Italy

    L. Maiorino

  8. Division of Medical Oncology, Santa Maria Hospital, Via Domitiana, 80078, Pozzuoli, Italy

    S. Tafuto

  9. Division of Medical Oncology, Da Procida Hospital, Via Calenda, 84100, Salerno, Italy

    G. De. Cataldis

Authors
  1. P. Comella
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Massidda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Palmeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Farris
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. De Lucia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Natale
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L. Maiorino
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Tafuto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. De. Cataldis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R. Casaretti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Comella.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Comella, P., Massidda, B., Palmeri, S. et al. Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study. Cancer Chemother Pharmacol 56, 481–486 (2005). https://doi.org/10.1007/s00280-005-1003-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-005-1003-6

Keywords

Search

Navigation